中脑胶质瘤的显微外科治疗:大样本单术者连续病例系列的手术结果与长期预后
该研究回顾性分析了2006年3月至2022年6月单术者连续54例中脑胶质瘤患者的显微外科治疗,其中儿童28例,低级别48例、高级别6例。全切除39例(72%),平均切除程度98.0%,无手术死亡,低级别患者全部存活且KPS无下降。作者认为显微外科可作为首选治疗。
要点
- 54例中脑胶质瘤(儿童28例,低级别48例、高级别6例)行显微手术,全切除率72%,平均切除程度98.0%。
- 无手术死亡,暂时性新发神经功能缺损9例,永久性2例。
- 平均随访72个月,48例低级别患者全部存活且KPS无下降,42例KPS较术前改善。
核心结论
- 中脑胶质瘤显微切除可行,手术结果和长期临床预后良好,尤其低级别胶质瘤患者;作者认为显微外科应被视为首选治疗。
研究设计与样本
- 回顾性分析2006年3月至2022年6月单术者连续54例中脑胶质瘤显微手术患者的前瞻性收集数据,其中儿童28例、高级别6例、低级别48例。
主要发现
- 54例中,被盖22例、中脑中央结构7例、顶盖25例,无1例起源于大脑脚。
- 全切除39例(72%),平均切除程度98.0%(中位100%,范围82%-100%)。
- 无手术死亡;暂时性新发神经功能缺损9例,永久性2例。
- 平均随访72个月(中位62,范围3-193个月),54例中49例仍存活;48例低级别患者全部存活且KPS无下降,其中42例较术前改善。
临床怎么用
- 作者认为显微外科应被视为中脑胶质瘤的首选治疗,尤其低级别胶质瘤患者。
- 作者指出充分的显微手术技术和麻醉管理,以及术前准确理解肿瘤确切地形起源和生长模式,对良好手术结果至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors report on a large, consecutive, single-surgeon series of patients undergoing microsurgical removal of midbrain gliomas. Emphasis is put on surgical indications, technique, and results as well as long-term oncological follow-up. METHODS: A retrospective analysis was performed of prospectively collected data from a consecutive series of patients undergoing microneurosurgery for midbrain gliomas from March 2006 through June 2022 at the authors' institution. According to the growth pattern and location of the lesion in the midbrain (tegmentum, central mesencephalic structures, and tectum), one of the following approaches was chosen: transsylvian (TS), extreme anterior interhemispheric transcallosal (eAIT), posterior interhemispheric transtentorial subsplenial (PITS), paramedian supracerebellar transtentorial (PST), perimedian supracerebellar (PeS), perimedian contralateral supracerebellar (PeCS), and transuvulotonsillar fissure (TUTF). Clinical and radiological data were gathered according to a standard protocol and reported according to common descriptive statistics. The main outcomes were rate of gross-total resection; extent of resection; occurrence of any complications; variation in Karnofsky Performance Status score at discharge, 3 months, and last follow-up; progression-free survival (PFS); and overall survival (OS). RESULTS: Fifty-four patients (28 of them pediatric) met the inclusion criteria (6 with high-grade and 48 with low-grade gliomas [LGGs]). Twenty-two tumors were in the tegmentum, 7 in the central mesencephalic structures, and 25 in the tectum. In no instance did the glioma originate in the cerebral peduncle. TS was performed in 2 patients, eAIT in 6, PITS in 23, PST in 16, PeS in 4, PeCS in 1, and TUTF in 2 patients. Gross-total resection was achieved in 39 patients (72%). The average extent of resection was 98.0% (median 100%, range 82%-100%). There were no deaths due to surgery. Nine patients experienced transient and 2 patients experienced permanent new neurological deficits. At a mean follow-up of 72 months (median 62, range 3-193 months), 49 of the 54 patients were still alive. All patients with LGGs (48/54) were alive with no decrease in their KPS score, whereas 42 showed improvement compared with their preoperative status. CONCLUSIONS: Microneurosurgical removal of midbrain gliomas is feasible with good surgical results and long-term clinical outcomes, particularly in patients with LGGs. As such, microneurosurgery should be considered as the first therapeutic option. Adequate microsurgical technique and anesthesiological management, along with an accurate preoperative understanding of the tumor's exact topographic origin and growth pattern, is crucial for a good surgical outcome.
引用
- Serra C, Türe H, Fırat Z, et al. Microsurgical management of midbrain gliomas: surgical results and long-term outcome in a large, single-surgeon, consecutive series. J Neurosurg. 2023. PMID: 37503951. doi:10.3171/2023.5.JNS222219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。